Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores the use of targeted therapies beyond the approved classes of JAK inhibitors, i.e. ruxolitinib and fedratinib, including combinatorial approaches as well as stand-alone, novel targeted therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть